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Abstract
Objective: To evaluate lung functional capacity (FC) for physical exercise in children and ado-
lescents with sickle cell disease (SCD) through the six-minutewalk test (6MWT).
Method: A cross-sectional prospective study was performed to evaluate the FC of 46 patients
with SCD through the 6MWT. The following parameters were assessed: heart rate (HR), respi-
ratory rate (RR), peripheral pulse oxygen saturation (SpO2), peak expiratory ﬂow (PEF), blood
pressure (systolic and diastolic), dyspnea, and leg fatigue (modiﬁed Borg scale) at rest, in the
end of the test, and ten minutes after the 6MWT. The total distance walked was also recorded.
For statistical analysis, the parametric variables were analyzed using the paired Student’s t-
test, analysis of variance (ANOVA), and Bonferroni multiple comparisons, with a signiﬁcance
level set at p≤ 0.05.
Results: The 46 patients were aged age 9.15± 3.06 years, presented baseline Hb of
9.49± 1.67 g/dL, and walked 480.89± 68.70 m. SCD diagnosis was as follows: group 1-
HbSS (n = 20)/HbS0-thalassemia (n = 3) and group 2 - HbSC (n = 20)/HbS+-thalassemia (n = 3).
Regarding total distance walked, patients in group 1 walked a shorter distance than patients
in group 2 (459.39± 57.19 vs. 502.39± 73.60 m; p = 0.032). There was no statistical difference
regarding PEF in the three moments of evaluation. The SpO2 in ambient air and SpO2 with O2
differed between groups 1 and 2 (p < 0.001 vs. p = 0.002), as well as the RR (p = 0.001).
Conclusion: These patients showed a lower FC for exercise than that predicted for the age range
in the literature. Patients diagnosed with HbSS/S0-thalassemia had a lower performance in the
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test than those with HbSC/S+-thalassemia regarding total distance walked, RR, and SpO2 after
the 6MWT.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.
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Avaliac¸ão da capacidade funcional para o exercício de crianc¸as e adolescentes com
doenc¸a falciforme pelo teste da caminhada de seis minutos
Resumo
Objetivo: Avaliar a capacidade funcional pulmonar (CF) para o exercício físico de crianc¸as e
adolescentes com doenc¸a falciforme (DF) pelo teste da caminhada de seis minutos (TC6’).
Métodos: Estudo transversal prospectivo avaliando a CF pelo TC6’ de 46 pacientes com DF.
Foram avaliados: frequência cardíaca (FC), frequência respiratória (FR), saturac¸ão de pulso
de oxigênio (SpO2), pico de ﬂuxo expiratório (PFE), pressão arterial (PA) sistólica e diastólica,
dispneia e cansac¸o em membros inferiores (escala de Borg modiﬁcada) em repouso, ao término
e 10 minutos após o TC6’ e a distância percorrida. Análise estatística: test t-Student pareado,
análise de variância e comparac¸ões múltiplas de Bonferroni, signiﬁcância p ≤ 0,05.
Resultados: Dos 46 pacientes, a média±dp da idade foi 9,15± 3,06 anos, hemoglobina basal
9,4± 1,67 g/dL e distância percorrida 480,89± 68,70 m. Diagnóstico da DF: Grupo 1-- HbSS
(n = 20)/HbS0-talassemia (n = 3); e Grupo 2 -- HbSC (n = 20)/ HbS+-talassemia (n = 3). O Grupo
1 apresentou menor distância percorrida do que o Grupo 2 (459,39± 57,19 vs 502,39± 73,60m;
p = 0,032). Não houve diferenc¸a estatística em relac¸ão ao PFE. A SpO2 em ar ambiente e a SpO2
com O2 (1 L/min) após o teste foi maior no Grupo 2 (p < 0,001 e p = 0,002, respectivamente). A
FR foi maior no Grupo 1 ao ﬁnal do TC6’ (p < 0,001).
Conclusão: Esta amostra apresentou CF para o exercício abaixo do predito para a faixa etária
na literatura. Os pacientes com HbSS/S0-talassemia apresentaram desempenho inferior na
distância percorrida, FR e SpO2 após o TC6′, comparativamente aos pacientes com HbSC/S+-
talassemia.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. Todos os direitos
reservados.
Introduction
Sickle cell anemia (HbSS) is the most common monogenic
hereditary disease in Brazil, with an estimated prevalence
of heterozygotes for HbS ranging from 2% to 8% in the gen-
eral population.1 HbSS, the most severe form of sickle cell
disease (SCD) is a hemoglobinopathy resulting from the sin-
gle amino acid substitution of a glutamic acid for a valine
at the sixth position of the beta globin chain, on chromo-
some 11, giving rise to hemoglobin S (HbS).2 This alteration
in hemoglobin is responsible for the anomalous form of ery-
throcytes, leading to hemolytic anemia, endothelial vascu-
lopathy, and vaso-occlusive phenomena, followed by tissue
ischemia and necrosis, with subsequent organ dysfunction,
which are responsible for the high mortality of SCD.1,2 SCD
occurs when HbS combines with another hemoglobinopathy,
such as C, D, -thalassemia, or another HbS.3
The lung is a major target organ of acute and chronic
complications in SCD; acute chest syndrome (ACS) is the
second most frequent cause of hospitalization in this pop-
ulation, with high rates of morbidity and mortality.4--6 It is
an acute complication usually triggered by a clinical picture
of infection. It can be deﬁned by a combination of signs
and symptoms, which include dyspnea, chest pain, fever,
cough, and a new pulmonary inﬁltrate.7 The proliferative
vasculopathy that occurs in sickle cell disease is the main
cause of the chronic pulmonary alterations that occur in
these patients.8
The chronic alterations and recurrent episodes of ACS
decrease the functional capacity (FC) in patients with SCD.
MacLean et al.,9 when assessing lung function in children
with SCD through spirometry, observed a restrictive pul-
monary pattern and a progressive reduction in lung volume.
Another prospective study,10 with patients aged 10 to 26
years, found alterations in pulmonary function, with a pre-
dominance of mixed or combined pattern.
Thus, the evaluation of FC should be part of outpatient
monitoring of these patients. However, studies assessing and
addressing the FC in children and adolescents with SCD are
limited.11 A simple and effective method to evaluate the FC
is to apply the six-minute walk Ttest (6MWT), which provides
information about functional status, oxygen consumption,
exercise tolerance, and patient survival according to test
performance.12,13 The 6MWT assesses the individual’s sub-
maximal effort, similar to the effort made in some daily life
activities, representing their FC to exercise.12
Although the 6MWT has not been widely studied in
patients with hemoglobinopathies, especially in pediatric
patients, preliminary data suggest that there may be a good
correlation among this test, maximum oxygen uptake, and
severity of pulmonary hypertension in adults with SCD.14
There are no published articles in the literature evaluat-
ing the FC in children and adolescents with SCD; thus this
study aimed to evaluate the FC to exercise in children and
adolescents with SCD using the 6MWT.
Methods
This was a prospective cross-sectional study evaluating 46
children and adolescents with SCD aged between 6 and
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18 years, distributed according to HbSS genotype, HbS0-
thalassemia, HbSC, and HbS+-thalassemia. The children
who were attended to at the pediatric hematology outpa-
tient clinic from April of 2009 to July of 2010 and met the
inclusion criteria were evaluated.
The FC of these patients was evaluated through the
6MWT, following the guidelines of the American Thoracic
Society.12 The study was approved by the Ethics Committee
in Research of the Escola Paulista de Medicina/Universidade
Federal de São Paulo (EPM/UNIFESP). Exclusion criteria were
patients with hemodynamic instability or neurological or
orthopedic diseases that limited exercise performance.
Basal hemoglobin (Hb) and history of hospitalizations for
pulmonary complications were collected from the patients’
medical records. The assessment of body mass (in kg) and
height (in m) was performed in a standardized manner, using
an anthropometric digital scale (Filizola®). The classiﬁcation
of nutritional status was performed using Z-score distribu-
tion for weight/age, height/age and body mass index (BMI).
The WHO AnthroPlus 2007 software of the World Health
Organization (WHO) was used to obtain the BMI and Z score
values.15
The 6MWT was performed in a 10-meter long corridor,
outdoors, withmarkings at everymeter and indicators on the
ground indicating the beginning and end of the trajectory. It
was decided to perform the test in a 10-meter corridor due
to the promising results in the ‘‘shuttle walk test’’, which
also uses this distance.16--20
Patients received theoretical and practical training
regarding the objectives of the 6MWT and how they should
perform it. Each patient underwent two tests (with a
30-minute interval between them); the test with best per-
formance was considered if the difference between tests
was less than 10% In case of a difference higher than 10%,
a new test would be performed. No patient had to perform
more than two tests.
The 6MWT was administered by two trained physical the-
rapists. At the beginning of the test, the patient was at rest
for 15 to 20minutes and had fasted for at least two hours. At
the end of six minutes, the patient stopped where he/she
was, and one of the therapists approached him/her with
a chair and assessment equipment in order to record the
total distance walked. The number of turns was counted
manually, and a stopwatch (Casio®) was used to mark the
time.
Water was offered to the patients before and after the
6MWT. All patients used oxygen during the test (nasal can-
nula 1 L/min), regardless of SpO2 on ambient air, in order
to prevent hypoxemia during exercise, due to the risk of a
vaso-occlusive crisis caused by SCD.
All variables were assessed at rest, at the end of the test,
and at 10minutes after it. The following parameters were
measured: systolic (SBP) and diastolic (DBP) blood pressure
with a BD® sphygmomanometer; respiratory rate (RR), SpO2,
and heart rate (HR) with a portable pulse oximeter (Dixtal®).
The peak expiratory ﬂow (PEF) was measured using an Assess
Peak Flow Meter® device; three measurements were taken
and the highest was considered.21 Dyspnea and lower-limb
fatigue were assessed by the modiﬁed Borg scale.21 All
variables were measured with the patient in the sitting posi-
tion, except for PEF, which was measured in the standing
position.
To analyze the behavior of SCD during the 6MWT, the sam-
ple was divided into two groups according to the disease
genotype. Group 1 consisted of patients with HbSS/HbS0-
thalassemia and group 2 consisted of patients with HbSC/
HbS+-thalassemia, as patients in group 1 tend to have a
more severe clinical course than those in group 2.22,23
Statistical analysis
Parametric variables were analyzed by paired Student’s t-
test and continuous measurements by ANOVA for repeated
measures. Multiple Bonferroni comparisons were made
between the two evaluation moments, and values were
considered statistically signiﬁcant when p ≤ 0.05. Results
are shown as mean± standard deviation (SD), median
(minimum-maximum), frequency, and percentage. The sta-
tistical analysis was performed using the Statistical Package
for Social Sciences (SPSS) release 15.0.
Results
This study evaluated 46 patients with SCD with the
following demographic characteristics, expressed as
mean± standard deviation (SD): age 9.15± 3.06 years;
basal Hb 9.49± 1.67 g/dL; weight 30.98± 11.30 kg;
height 1.34± 0.16 m; BMI 16.63± 2.40 kg/m2; percentile
weight/age 49.29± 26.57; height/age 42.83± 25.92; and
BMI/age 46.86± 24.70. The Z-scores for all anthropo-
metric indices were: weight/age 0.04± 1.03; height/age
0.22± 0.95; and BMI/age 0.20± 1.26. The total distance
walked during the 6MWT was 480.89± 68.70 m.
Patients in group 1 and group 2 were similar regarding
age, gender, and anthropometric variables; group 1 had
lower mean Hb values and higher frequency of pneumonia
and/or ACS than group 2 (Table 1). The distance walked by
patients in group 1 was signiﬁcantly shorter than that of
patients in group 2 (459.39± 57.19 vs. 502.39± 73.60 m,
p = 0.032 - Table 1).
Analyzing the 46 patients, it was observed that the car-
diorespiratory variables (HR and RR) differed only at the
end of the 6MWT compared to the other moments in time
(p < 0.001). SBP and DBP decreased signiﬁcantly ten minutes
after the end of the 6MWT, when compared to measurements
at the end of the test (p = 0.003, p < 0.001) (Table 2).
There was no statistical difference regarding PEF (L/min)
between the three moments in time, as well as in the eval-
uation of lower-limb stress and fatigue assessed by the Borg
scale (Table 3).
Table 4 presents the description of the variables mea-
sured during the 6MWT (at rest, end of the test and ten
minutes after the 6MWT) in groups 1 and 2. When per-
forming multiple comparisons of mean differences between
the moments when cardiorespiratory and respiratory varia-
bles were measured in Groups 1 and 2, it was observed
(means of measurements/standard error; p) at rest vs.
end of the 6MWT that there was an increase in HR (-
10.83/2.50; p < 0.001), RR (-4.50/0.56; p < 0.001), SBP
(-3.85 / 1.50, p = 0.052) and DBP (-3.09/1.48, p = 0.119); rest
vs. ten minutes after the end of the 6MWT, a decrease in
HR (0.76/2.93, p = 1), RR (0.41/0.70, p = 1), SBP (1.41/2.03,
p = 1) and DBP (2.80/1.76, p = 0.343); end of the 6MWT vs.
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Table 1 Demographic and clinical data and distance walked in the six-minute walk test by the HbSS/S0-thalassemia and
HbSC/S+-thalassemia groups.
HbSS / S0-thalassemia
group 1
HbSC / S+-thalassemia
group 2
p
Demographic data
Age (years) 9.21± 3.45 9.08± 2.69 0.887
Gender (%) 56.53 (male) 52.17 (male) 0.767a
Weight (Kg) 30.85± 13.31 31.11± 9.16 0.939
Height (m) 1.34± 0.18 1.34± 0.14 0.956
Body mass index 16.37± 2.67 16.89± 2.13 0.472
Hb (mean g/dL) 8.26± 1.33 10.70± 0.90 < 0.001
Hospitalizations due to pulmonary complications 0.001b
PNM % (n) 47.82 (11) 34.78 (8)
ACS % (n) 26.08 (6) 0.0
ACS and PNM % (n) 13.05 (3) 8.70 (2)
No complications % (n) 13.05 (3) 56.52 (13)
Distance walked (m) 459.30± 57.19 502.39± 73.6 0.032
Tests, Student’s t-test; ACS, acute chest syndrome; n, number; m, meters; PNM, pneumonias.
a chi-squared.
b likelihood ratio.
Table 2 Respiratory and cardiorespiratory variables of children and adolescents with sickle cell disease submitted to the
six-minute walk test.
Variables Rest End of test (sixth minute) Ten minutes after end of the test p
HR (bpm) 91.93 ± 13.0 102.76 ± 20.3a 91.17 ± 12.1 < 0.001
SpO2 c/ O2 (%) 97.46 ± 1.9 97.20 ± 1.9 - 0.183
SpO2 AA (%) 95.15 ± 3.3 - 95.72 ± 3.0 0.053
RR (rpm) 21.67 ± 4.4 26.17 ± 5.0a 21.26 ± 4.2 < 0.001
SBP (mmHg) 99.37 ± 11.6 103.22 ± 15.4 97.96 ± 11.6a 0.003
DBP (mmHg) 59.26 ± 10.0 62.35 ± 10.2 56.46 ± 7.9a < 0.001
bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; mmHg, millimeters of mercury; rpm, respirations per minute; RR,
respiratory rate; SBP, systolic blood pressure; SpO2 AA, pulse oxygen saturation with ambient air; SpO2 w/ O2, pulse oxygen saturation
with oxygen (1 L/min).
aTest: analysis of variance with repeated measures, with two factors.
ten minutes after the end of the 6MWT, a decrease in
HR (11.59/2.50; p < 0.001), RR (4.91/0.56, p < 0.001), SBP
(5.26/1.59, p = 0.004) and DBP (5.89/1.48, p < 0.001). When
comparing rest vs. ten minutes after the end of the 6MWT,
there was an increase in SpO2 AA (-3.65/0.53; p < 0.001).
When comparing Groups 1 and 2 at rest vs. six minutes after
the end of the 6MWT there was an increase in SpO2 with O2
(-1.57/0.47, p = 0.002).
Discussion
This study demonstrated that 65.21% of patients had a his-
tory of hospitalizations for pulmonary complications (ACS
and/or pneumonia). People with a history of recurrent
ACS have lower peak maximum oxygen consumption (VO2)
and greater possibility of chronic lung injury, which may
have an important impact on FC for exercise.11 Pulmonary
Table 3 Modiﬁed Borg scale and peak expiratory ﬂow of children and adolescents with sickle cell disease submitted to the
six-minute walk test.
Variables Rest End of the test (Sixth minute) Ten minutes after end of the test p
Borg Da 0 (0-3) 0 (0-9) 0 (0-4) -
Borg LLLLa 0 (0-5) 1 (0-10) 0 (0-9) -
PEF (L/min) 223.04± 65.92 231.63± 76.65 226.63± 67.06 0.074
Borg D, Borg of dyspnea; Borg LLLL, Borg of lower limbs; L/min, liters per minute; PEF, peak expiratory ﬂow.
Test: analysis of variance with repeated measures, with two factors.
a Variables as median (minimum-maximum).
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Table 4 Description of variables at the moments (at rest, end of the test, and ten minutes after the test) in the HbSS/HbS0
-thalassemia and HbSC/HbS + -thalassemia groups.
Diagnosis
Variable Moment Group 1 (n = 23) Group 2 (n = 23)
Mean SD Mean SD
Rest 94.61 11.93 89.26 13.73
HR (bpm) End of the test (sixth minute) 105.65 19.44 99.87 21.25
Ten minutes after end of test 94.39 12.13 87.96 11.48
SpO2 AA (%) Rest 93.13 3.55 97.17 1.07
Ten minutes after end of test 94.09 3.41 97.35 0.88
SpO2 with O2 (%) Rest 96.70 2.30 98.22 0.74
End of the test (sixth minute) 96.39 2.25 98.00 1.13
Rest 23.30 4.33 20.04 3.84
RR (rpm) End of the test (sixth minute) 28.30 5.34 24.04 3.66
Ten minutes after end of test 22.65 4.32 19.87 3.66
Rest 101.74 13.02 97.00 9.80
SBP (mmHg) End of the test (sixth minute) 104.78 18.55 101.65 11.65
Ten minutes after end of test 98.70 12.54 97.22 10.85
Rest 57.39 10.96 61.13 8.86
DBP (mmHg) End of the test (6th minute) 61.74 11.14 62.96 9.27
Ten minutes after end of test 55.22 9.59 57.70 5.75
Rest 223.04 64.77 223.04 68.50
PEF (L/min) End of the test (sixth minute) 234.57 78.78 228.70 76.12
Ten minutes after end of test 223.70 66.83 229.57 68.65
bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; L/min, liters/minute; mmHg, millimeters of mercury; RR, respi-
ratory rate; rpm, respirations per minute; SBP, systolic blood pressure; PEF, peak expiratory ﬂow; SpO2 AA, pulse oxygen saturation with
ambient air; SpO2 w/ O2, pulse oxygen saturation with oxygen (1 L/min).
complications were similar to those reported in literature:
86.95% of patients in group 1 had a history of hospitaliza-
tion for pulmonary complications (pneumonia and/or ACS),
whereas in group 2 the incidence was 43.48%. Clinical man-
ifestations of SCD, in general, are more severe in patients
with HbSS and HbS0-thalassemia, and ACS is more frequent
in this group.6,23
The total distance walked in the 6MWT by healthy chil-
dren is inﬂuenced by age, height, and weight: it is inversely
proportional to weight and directly proportional to age and
height.24 Although the nutritional status of the patients were
within the mean normal values, differing from other stud-
ies in SCD where patients tend to be malnourished,25,26 the
distance walked during the 6MWT was shorter than that pre-
dicted for age and height,27--29 meaning that factors other
than weight and height, such as hemoglobin value and the
occurrence of ACS, may be related to these ﬁndings.
When comparing the total distance walked, patients in
group 2 walked a signiﬁcantly longer distance than those
in group 1. These results may be related to the fact that
patients with HbSS and S0-thalassemia have a clinically
more severe form of the disease, with lower basal Hb val-
ues and greater number of hospitalizations for pulmonary
complications, which may have also caused a signiﬁcant dif-
ference in the comparison of the two groups regarding SpO2
and RR during the 6MWT.
Liem et al.11 evaluated FC in 30 children and ado-
lescents with SCD undergoing exercise testing, and found
FC limitation ranging from moderate to severe. FC for
exercise was signiﬁcantly lower in children with a history
of recurrent ACS. and was related to the level of basal
Hb (9.5± 1.6 g/dL), similar to values found in this study
(9.49± 1.67 g/dL - Table 1).
Most children and adolescents adapt to the increased car-
diac demand caused by chronic anemia, and generally have
a 50% to 75% reduced exercise capacity.30 Chronic anemia
can lead to lower tissue oxygenation, mainly during exer-
cise, in which the use of oxygen is increased to meet the
demand for energy. In SCD, some compensatory mechanisms
prevent this from occurring, such as increased heart rate
during exercise, increased systolic volume, and decreased
peripheral vascular resistance, reducing the resistance of
sickle erythrocytes in capillary transit and oxygen supply
to the tissues, thus allowing close to normal saturation in
the mixed venous blood.31,32 This could explain the present
results of a signiﬁcant increase in HR at the end of the 6MWT
without signiﬁcant changes in SpO2.
The study by Campbell et al.32 concluded that the
exercise-induced SpO2 decrease was more related to the
degree of anemia and hemolysis than to previous history
of ACS and severe pain. Lammers et al.33 demonstrated
that SpO2 varies little during the 6MWT in healthy children,
whereas there is an increase in HR and RR. In the present
study, a signiﬁcant increase in HR, RR and SpO2 with O2 was
observed at the end of the 6MWT.
SBP in patients with SCD is described as normal and DBP as
decreased, resulting in a lower mean arterial pressure.34 The
response observed in this study, a decrease in SBP and DBP
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ten minutes after the 6MWT, may be related to the decrease
in HR and consequent decrease in cardiac output, main-
taining vasodilation for a period of time after the exercise,
which was also described in other studies.35,36
A subjective method of dyspnea and fatigue assessment
is through the Borg scale.21 The Borg scale can be used as an
aid to the 6MWT, allowing for the evaluation of the degree
of respiratory distress according to the patient’s perception
through subjective indices.12 In this study, there were no
signiﬁcant changes in respiratory distress of patients during
the 6MWT, which may have been due to the oxygen supplied
to patients (nasal cannula 1L/min) during the 6MWT.
When evaluating PEF, there was no statistical difference
among the three moments in time (Table 3). Lower PEF in
asthmatic children is related to disease symptoms and the
risk of exacerbation.37 In the present sample of children with
SCD, there was no difference between groups 1 and 2 when
PEF was evaluated at rest.
Regarding the variables analyzed during the test, it was
observed that SpO2 in ambient air (AA SpO2) and SpO2 with 1
L/min of O2 were on average signiﬁcantly higher in group 1
than in group 2. Signiﬁcant differences were also found for
RR, and higher values were observed in group 1 regardless
of the time of evaluation. These ﬁndings may be related to
the fact that pulmonary complications were more frequent
in group 1.
This is a novel study; however, it has the limitation of
using a 10-meter corridor to perform the 6MWT, whereas
the ATS recommends a 30-meter corridor.12 Despite the rec-
ommendation of the ATS, some studies38--40 applied different
lengths for the 6MWT. Sciurba et al.40 stated that the length
of the track is not the most important feature of the 6MWT.
The standardization of the shuttle walk test recommends
the use of a 10-meter corridor,19 and there is a reference
value for the distance traveled (544.28± 131.13 meters)
for Brazilian children (mean age± SD: 11.28± 1.85 years).20
This study sample showed low predicted values for the dis-
tance walked in the 10-meter corridor, when compared to
healthy Brazilian children.
It can be concluded that this sample of children and
adolescents with SCD had FC for exercise below that pre-
dicted for the age range when compared to healthy children.
Patients diagnosed with HbSS/S0-thalassemia had a worse
performance regarding total distance walked, HR, and SpO2
after 6MWT when compared to patients with HbSC/S+-
thalassemia. It is suggested that other studies should be
conducted with similar designs for evaluation of FC in
patients of this age group with SCD, as they show alterations
in FC, which are related to the disease prognosis and quality
of life.
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